WO2023217813 - EXCIPIENTS FOR PURIFICATION AND VIRUS FILTRATION OF BIOLOGICAL FLUIDS
National phase entry is expected:
Publication Number
WO/2023/217813
Publication Date
16.11.2023
International Application No.
PCT/EP2023/062340
International Filing Date
10.05.2023
Title **
[English]
EXCIPIENTS FOR PURIFICATION AND VIRUS FILTRATION OF BIOLOGICAL FLUIDS
[French]
EXCIPIENTS POUR LA PURIFICATION ET LA FILTRATION DE VIRUS DE FLUIDES BIOLOGIQUES
Applicants **
MERCK PATENT GMBH
Frankfurter Strasse 250
64293 Darmstadt, DE
Inventors
CACACE, Benjamin
c/o EMD Millipore Corporation [Burlington]
400 Summit Drive
Massachusetts
BURLINGTON, MA 01803, US
ELDO, Joby
c/o EMD Millipore Corporation [Burlington]
400 Summit Drive
Massachusetts
BURLINGTON, MA 01803, US
CARBRELLO, Christina
c/o EMD Millipore Corporation [Burlington]
400 Summit Drive
Massachusetts
BURLINGTON, MA 01803, US
ROSENKRANZ, Tobias
c/o Merck Life Science KGaA
Frankfurter Strasse 250
64293 Darmstadt, DE
Priority Data
63/341,088
12.05.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1249 | |
| EPO | Filing, Examination | 5913 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2710 |
Total: 11034 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Methods are disclosed for filtering a biological fluid that includes housing a surface treated porous membrane in a filtration device, optionally a virus filtration device, having an input and an output; introducing a biological fluid into the input of the filtration device wherein an aromatic excipient is added to the biological fluid; and collecting a filtrate from the output. In some embodiments, the biological fluid comprises a monoclonal antibody solution, a protein-containing solution, a solution containing fragment antigen-binding fragments, a solution containing recombinant proteins, or a fractionated plasma product.[French]
Des procédés sont divulgués pour filtrer un fluide biologique qui consistent à loger une membrane poreuse traitée en surface dans un dispositif de filtration, éventuellement un dispositif de filtration de virus, ayant une entrée et une sortie ; à introduire un fluide biologique dans l'entrée du dispositif de filtration, un excipient aromatique étant ajouté au fluide biologique ; et à collecter un filtrat à partir de la sortie. Dans certains modes de réalisation, le fluide biologique comprend une solution d'anticorps monoclonal, une solution contenant des protéines, une solution contenant des fragments de liaison à l'antigène de fragment, une solution contenant des protéines recombinantes, ou un produit de plasma fractionné.